

42
35. (New) The peptide of claim 32, wherein said mutant is selected from the group consisting of a peptide with a mutation in His 470, a peptide with a mutation in Arg 469, a peptide with a mutation in Trp 383, a peptide with a mutation in Arg 386.

43
36. (New) The peptide of claim 32, wherein said mutant is selected from the group consisting of a peptide with a mutation in Arg 386, a peptide with a mutation in Phe 253, a peptide with a mutation in Arg 274, a peptide with a mutation in Trp 338, and a peptide with a combination of any of said mutations in Arg. 386, Phe 253, Arg 274 and Trp 338.

REMARKS

Applicants have corrected the errors to the specification pointed out by the Examiner.

New claims 29-36 are pending in the application. Claims 1-8 and 20-28 were canceled. Claims 9-19 and 29-35 have been withdrawn from consideration as being drawn to a non-elected invention. Applicants thank the Examiner for examining all seven peptides of listed in Table 1.

Support for new claims 29-36 is found in the specification, particularly at pages 3-5 and in the claims as originally filed.


The rejections of claims 9-19 and 29-35 have been mooted by withdrawal of these claims from consideration. The amendments presented above are believed to claim the subject matter which is described in the disclosure, and to more particularly point out and distinctly claim the subject matter which the Applicants consider to be the invention.

Thus, the amendments are believed to overcome the 35 U.S.C. 112, first and second paragraph rejections of claims 1-8 and 20-28. Reconsideration and withdrawal are deemed proper.

In view of the foregoing, reconsideration of the outstanding rejections, and the allowance of claims 29-36 are respectfully urged.

Respectfully submitted,

Customer No. address 23622


Gabriel P. Katona
Attorney of Record

It is hereby certified that this is being mailed on November 21, 2002

